• Like
New Models of Innovation in Life Sciences - MaRS Market Insights
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

New Models of Innovation in Life Sciences - MaRS Market Insights

  • 1,621 views
Published

Increasing costs and decreased productivity have hampered growth and investment in the global life sciences and health-care sector. The open-innovation approach embraced by many industries could …

Increasing costs and decreased productivity have hampered growth and investment in the global life sciences and health-care sector. The open-innovation approach embraced by many industries could transform the way biotech and health-care companies innovate—bringing products and services to market quickly and efficiently.

What does this mean for business and consumers in Ontario?

Presenting diverse perspectives, this breakfast panel examines the open-innovation approach and identifies opportunities and challenges for health-care stakeholders as they position themselves in the value chain. Learn how to use this approach and leverage it with success.

Published in Business , Technology , Education
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
1,621
On SlideShare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
65
Comments
0
Likes
2

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Pfizer CanadaTo Be Truly Healthy,It Takes More Than Medication
  • 2. Innovation Gap
  • 3. Innovation Gap!  “We intend to make our internal capability even more effective by tapping into the best scientific capability outside of our walls -wherever it exists. That’s why we are reaching out to scientists around the world.” Jeff Kindler, CEO, Pfizer
  • 4. Understanding Disease Biology is not aCompetitive Activity
  • 5. Canadian Public-Private Partnership Modelsof Innovation Pre-Competitive Partnership Models of Innovation Competitive Collaborative R&D Partnerships Centers of Excellence in Commercialization (CECRs) Quebec Pain Research Network (QPRN) Ontario Institute of Cancer Research (OICR) Center for Drug Research & Discovery (CDRD) Pre-Competitive R&D Partnerships Quebec Drug Discovery Consortium (CQDM) Structural Genomics Consortium (SGC)
  • 6. Canadian Public-Private Partnership Modelsof Innovation World class science drives the day…… Very significant internal competition for global R&D $$s Local affiliates can drive internal global recognition of local opportunities, through local resources and local funds. Alignment with large consortia and public funding is very helpful IRMA : THE DRUG In the Future REPOSITIONING INITIATIVE Public-Private and Pre-competitive research is growing ON is in position to excel in this emerging paradigm Public support of PPP is not a temporary concept. Funding must be maintained, as a basis for attracting other $$s into the project.
  • 7. Enable Integrate EngageA New Model for the Translation of Regenerative Medicine: Collaborative, Capital-Efficient Technology Development New Models of Innovation in Life Sciences April 20th, 2011, MaRS, Toronto Michael H. May PhD CEO Slide 1
  • 8. “Open Innovation” is Not New OpenCollaboration Innovation Non-Zero-Sum GainTechnology Zero-Sum GainEnvironmentalStress or Need Competition “NONZERO – The Logic of Human Destiny”, Robert Wright Slide 2
  • 9. Funding of Research andCommercialization in Canada Slide 3
  • 10. CCRM Builds on MaRS and MI!"#$%&()*%&#+!#,-..-*%# /%%)/..0#*%#123# Slide 4
  • 11. A Global Nexus for RM Technology and Commercialization Mission: To bridge the RM commercialization gap by leveraging funding and infrastructure, and mobilizing business and scientific expertise to translate technologies Existing IndustryGovernment Investment Programs Capital Pre- Clinical & Product Basic R&D Commercial Commercial Development Validation Validation Slide 5
  • 12. Our Plan to Bridge the RM Commercialization Gap Existing IndustryGovernment Investment Programs Capital Enable Product Integrate Science and Create Links Development Business to Market Slide 6
  • 13. Translation through Collaboration Slide 7
  • 14.   capital efficient RM development  utilize academic infrastructure  facilitate global collaboration  focus on key bottlenecks  explore alternative funding sources Slide 8
  • 15. Slide 9
  • 16. Industry Engagement Platform 1 Platform 2 Platform 3 4 companies, 2 6 companies, 2 6 companies, 2Canadian, 2 large Canadian, 3 large Canadian, 1 large and 3 small and 3 small and 5 small Community Offerings Market Needs !  iPSC cells !  Lineage reprogramming Characterized and validated !  Stem cell characterization stem cell lines and standardization Clinical and commercial !  Cell culture bioprocesses, quantities of stem/differentiated sensors and scale-up / out cells !  Biomaterials/biocompatibility !  Therapeutic polymers Tissue mimetics for drug !  Microfabrication screening & transplantation !  Functional and stabilized, cell-derived tissues Foundational Reagents, tools and processes Slide 10
  • 17. Driving Open InnovationCollaboration Non-Zero-Sum Gain "  Capital efficientTechnology "  Pre-competitive Zero-Sum GainEnvironmentalStress or Need Slide 11
  • 18. evidence-based infection control
  • 19. Evidence-based Infection Control!#$%"&()*+",-./0)$%"1%0-*"*2-34)*"3)*5%)6"$(*7"7-)(8/4/6"/*/6943(:"5)";)*5)%:";-/($%-:"/*1";8%)0-")$53);-(<"#$%"=)/6+">-68"/3.-0-"/*1"-?3--1"8/4-*5"(/2-59";8-%/40-("@"8%)%4-("A"B-/%("C$;$6/40-"D-/%**7+"E(-/(-"($%0-66/*3-"/*1"*2-34)*"3)*5%)6"()6$4)*(<"F "G)()3);/6"3/(-";/*/7-;-*5"F "H$5);/5-1"./*1".97-*-"3);86/*3-";)*5)%*7"F "H$5);/5-1")$5I%-/J"3)*5/35"5%/3*7""F "K>)5L(8)5M"1-*4N3/4)*"F "O-/6L4;-"@"($(5/*-1"5%/3J*7:"/6-%5("@";-5%3(" !"
  • 20. Innovation in Healthcare...!Incremental innovation tends to be ‘evolutionary’. Small improvements in existing practices.!Disruptive innovation improves a product or service in ways that the market does not expect and looks to make significant impacts.!Goal in healthcare is affordability/sustainability while increasing accessibility, quality and safety. This sector should be an ideal target for disruptive solutions.! 3
  • 21. Open Innovation!• C)*0-%7-*3-"Q)6$4)*"• R/%5*-%("S5."H67*-1"=)/6("• C)*N%;"&()*"/*1"R/5."• T/*5/*"5.-"&()*"• =-5M-%"E)*-" P"
  • 22. !"#$%&"()*+",-"./&-"0--,1$2,-" 34&"5#"
  • 23. 5#6",/&-"$77&%%"%70&-7&"•  8,9:&*"0-";<<="(,">&-&9$(&"?-,@A&*>&"$B,)("4):$-"/9,(&0-%"•  C&%)A(%"$-*"9&$>&-(%"0-(,"/)BA07"*,:$0-"@0(4,)("9&%(9072,-"•  D,"-,("EA&"F,9"GH",-"$-+"9&%)A(%"•  =<I",F">A,B$A",)(/)(",F"-&@"4):$-"$-*"/$9$%0(&"/9,(&0-"%(9)7()9&%"•  ;"/$/&9%"/&9"@&&?"
  • 24. !"/)BA07J/901$(&"/$9(-&9%40/" @&*&-" H4$9:$"#$-$*$" .-($90," K&AA7,:&"39)%("
  • 25. Industrial focus yields HQPFormer SGC members:•  > 65 scientists went on to jobs in academia •  15 to leadership positions (7 Faculty positions)•  > 33 to industry (9 to leadership positions)•  7 returned to the SGC/or relocated to another SGC site•  4 to business schoolsTraining at SGC:•  187 external scientists trained at the SGC (20 coop students)
  • 26. No IP facilitates collaboration•  More than 200 Collaborations in 17 countries world wide•  ~250 publications – an average of 3.1 non-SGC scientists per paper 1 collaboration 2-5 collaborations >1000 expression clones have been sent 5-10 collaborations out during the past 3 years of which more 10-20 collaborations than 800 to academia > 20 collaborations
  • 27. Knowledge transfer•  Over the last 3 years SGC scientists attended >250 conferences the majority of them as speakers•  Serve on SAB s of 5 biotech companies; 3 research consortia and 2 fundingagencies•  The SGC organised 20 workshops/conferences during the past three years•  More than 50 face-to-face meetings with industry per year•  More than 100 external scientists attended workshops held at SGC
  • 28. Technology developmentSGC driven developments: !  Lex System !  BeeHive (w. MolSoft, Inovacia, CPR) !  iSee (MolSoft) !  Software for domain boundary analysis !  Expression clone generating platform !  Phage-resistant bacterial host strains !  Proximity assay!Testing and Improvement of a number of different products/machines in collaboration with vendors:Crystallisation: !  JCSG+ crystallization screen !  Mosquito crystallization robot !  Minstrel imaging robot !  Actor anti-icing lid !  SpearLab Liquid nitrogen handling dewars Compound screening !  Stratagene/Agilent RT-PCR !  Stargazer !  BMG Labtech multi-functional plate reader "Polarstar Omega“ !  Biacore with GE Healthcare Other !  Contur ELN
  • 29. CommercializationHarbinger Biotech, founded in 2005, has sold equipment to over30 labs in industry and academia in Asia, North America andEuropeSGC software programs distributed to >40 labs1DegreeBio founded in 2010
  • 30. Moving the Pre-Competitive Boundary H)BA07LH901$(&" H)BA07" G-*)%(9+" H$9(-&9%40/" D,:$0-" Chemical Target Drug Probes Validation Discovery Screening No IP (re)Screening Chemistry No restrictions Chemistry Structure Publication Lead optimization Bioavailability Pharmacology DMPK Toxicology Chemical development Clinical development Creative commons Proprietary
  • 31. Impact of novel BET probe 250+ labs across the globeIdentified Published Distributed Jan 10 Sep 10 Jan 11